South Korea · Delayed Price · Currency is KRW Keeps Biopharma Statistics
Total Valuation
Keeps Biopharma has a market cap or net worth of KRW 169.86 billion. The enterprise value is 255.37 billion.
| Market Cap | 169.86B |
| Enterprise Value | 255.37B |
Important Dates
The next estimated earnings date is Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Keeps Biopharma has 20.08 million shares outstanding. The number of shares has increased by 3.91% in one year.
| Current Share Class | 20.08M |
| Shares Outstanding | 20.08M |
| Shares Change (YoY) | +3.91% |
| Shares Change (QoQ) | -0.12% |
| Owned by Insiders (%) | 4.13% |
| Owned by Institutions (%) | 4.23% |
| Float | 14.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.00 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 16.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 59.39, with an EV/FCF ratio of -5.45.
| EV / Earnings | -26.10 |
| EV / Sales | 1.50 |
| EV / EBITDA | 59.39 |
| EV / EBIT | n/a |
| EV / FCF | -5.45 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 1.14.
| Current Ratio | 1.15 |
| Quick Ratio | 0.54 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | 15.27 |
| Debt / FCF | -1.98 |
| Interest Coverage | 0.22 |
Financial Efficiency
Return on equity (ROE) is -14.33% and return on invested capital (ROIC) is 1.17%.
| Return on Equity (ROE) | -14.33% |
| Return on Assets (ROA) | 0.49% |
| Return on Invested Capital (ROIC) | 1.17% |
| Return on Capital Employed (ROCE) | 1.09% |
| Weighted Average Cost of Capital (WACC) | 9.47% |
| Revenue Per Employee | 1.56B |
| Profits Per Employee | -89.77M |
| Employee Count | 109 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 5.10 |
Taxes
| Income Tax | -1.32B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.04% in the last 52 weeks. The beta is 1.28, so Keeps Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -19.04% |
| 50-Day Moving Average | 8,159.40 |
| 200-Day Moving Average | 10,842.95 |
| Relative Strength Index (RSI) | 55.90 |
| Average Volume (20 Days) | 62,452 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Keeps Biopharma had revenue of KRW 170.15 billion and -9.79 billion in losses. Loss per share was -499.00.
| Revenue | 170.15B |
| Gross Profit | 37.58B |
| Operating Income | 1.57B |
| Pretax Income | -11.70B |
| Net Income | -9.79B |
| EBITDA | 6.06B |
| EBIT | 1.57B |
| Loss Per Share | -499.00 |
Balance Sheet
The company has 26.57 billion in cash and 92.59 billion in debt, with a net cash position of -66.02 billion or -3,288.24 per share.
| Cash & Cash Equivalents | 26.57B |
| Total Debt | 92.59B |
| Net Cash | -66.02B |
| Net Cash Per Share | -3,288.24 |
| Equity (Book Value) | 81.50B |
| Book Value Per Share | 3,092.30 |
| Working Capital | 12.97B |
Cash Flow
In the last 12 months, operating cash flow was -14.92 billion and capital expenditures -31.93 billion, giving a free cash flow of -46.85 billion.
| Operating Cash Flow | -14.92B |
| Capital Expenditures | -31.93B |
| Depreciation & Amortization | 4.49B |
| Net Borrowing | 62.25B |
| Free Cash Flow | -46.85B |
| FCF Per Share | -2,333.58 |
Margins
Gross margin is 22.08%, with operating and profit margins of 0.93% and -5.75%.
| Gross Margin | 22.08% |
| Operating Margin | 0.93% |
| Pretax Margin | -6.88% |
| Profit Margin | -5.75% |
| EBITDA Margin | 3.56% |
| EBIT Margin | 0.93% |
| FCF Margin | n/a |
Dividends & Yields
Keeps Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.91% |
| Shareholder Yield | -3.91% |
| Earnings Yield | -5.76% |
| FCF Yield | -27.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 20, 2020. It was a forward split with a ratio of 3.
| Last Split Date | May 20, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Keeps Biopharma has an Altman Z-Score of 1.67 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.67 |
| Piotroski F-Score | 3 |